Beyond alleviating symptomatic manifestations, the trajectory of NF-κB-targeted therapies should encompass the development of interventions capable of arresting or decelerating the inherent progression of the disease, thereby confronting the fundamental causes of AD [42]. Here, NFKB1 is linked to Alzheimer disease.